-
-
免疫系统人源化模型
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC混合接种模型
显示更多 -
-
体内肿瘤实验平台
显示更多 -
体外杀伤实验平台
显示更多 -
鼠源免疫系统模型
显示更多 -
肿瘤疫苗
显示更多 -
细胞疗法
显示更多 -
体外检测平台
显示更多 -
非GLP毒理平台
显示更多 -
非肿瘤模型及药效评价平台
-
系统性接种模型
-
非肿瘤模型及药效评价平台
-
皮肤损伤模型
-
脑卒中模型
-
肝纤维化模型
-
糖尿病模型
-
痛风性关节炎(GA)模型
-
肺纤维化模型
-
系统性红斑狼疮(SLE)模型
-
炎症性肠病(IBD)模型
-
类风湿性关节炎(RA)模型
显示更多 -
-
-
-
PDX模型
-
PDX模型
-
人头颈癌
-
眼癌
-
肺癌
-
人乳腺癌
-
人食管癌
-
人胃癌
-
人结直肠癌
-
人肝癌
-
胆管癌
-
胆囊癌
-
人胰腺癌
-
人肾癌
-
人膀胱癌
-
人输尿管癌
-
人前列腺癌
-
人子宫癌
-
人子宫颈癌
-
人卵巢癌
-
人皮肤癌
-
肉瘤
-
人神经系统癌
-
胚胎性癌
-
人淋巴瘤
-
人白血病
-
人骨髓瘤
-
肾上腺
-
间皮瘤
-
人其他
显示更多 -
-
CDX模型
-
CDX模型
-
人头颈癌
-
眼癌
-
肺癌
-
人乳腺癌
-
人食管癌
-
人胃癌
-
人结直肠癌
-
人肝癌
-
胆管癌
-
胆囊癌
-
人胰腺癌
-
人肾癌
-
人膀胱癌
-
人输尿管癌
-
人前列腺癌
-
人子宫癌
-
人子宫颈癌
-
人卵巢癌
-
人皮肤癌
-
肉瘤
-
人神经系统癌
-
胚胎性癌
-
人淋巴瘤
-
人白血病
-
人骨髓瘤
-
肾上腺
-
间皮瘤
-
人其他
显示更多 -
-
同源模型
-
同源模型
-
头颈癌
-
眼癌
-
肺癌
-
乳腺癌
-
胃癌
-
肝癌
-
胆管癌
-
胆囊癌
-
胰腺癌
-
肾癌
-
膀胱癌
-
输尿管癌
-
前列腺癌
-
子宫癌
-
子宫颈癌
-
卵巢癌
-
食管癌
-
皮肤癌
-
肉瘤
-
神经系统癌
-
胚胎性癌
-
淋巴瘤
-
白血病
-
骨髓瘤
-
肾上腺
-
间皮瘤
-
其他
-
结直肠癌
显示更多 -
-
团队介绍
——
CM05369
CM05369
| Key word | 结直肠癌, PDX, 体内药效,体外药效,免疫系统人源化,5-FU, DM1, DS8201, DXD, SN38, TAS-102, 奥沙利铂, 奥希替尼, 多西他赛, 恩考拉非尼, 吉西他滨, 拉帕替尼, 雷替曲塞, 芦康莎妥珠单抗, 曲美替尼, 顺铂, 丝裂霉素C, 依维莫司, 长春新碱, 紫杉醇, |
Model Information
| Model ID | CM05369 |
| Cancer Type | 结直肠癌(肝转移) |
| Cell Subtype | 腺癌 |
| Differentiation | 中分化 |
| Collection Site | 肝 |
| Metastatic Site | 肝转移 |
| Grade | II |
| TNM staging | ypT3N0M1a |
| IHC diagnosis | EGFR(3+),HER2(0),KI67(+80%),MLH1(+),MSH2(+),MSH6(+),PMS2(+)。Cmet(2+),EGFR(-),HER2(2+),KI67(90%),MLH1(+),MSH2(+),MSH6(+),PMS2(+),AFP(-),Hep(+),SALL4(-)。 |
| Pathology diagnosis | 临床诊断:直乙交界中低分化腺癌同时性肝转诊断意见 1.(肝方叶部分): 肝组织中可见中分化腺癌,结合临床,符合肠肝转移,大小2.0×1.5×1.5cm; 癌细胞坏死率约30%; 癌延伸至肝灼烧缘; 2.(肝S4部分) 肝组织中可见中分化腺癌,结合临床,符合肠癌肝转移,直径0.7cm; 癌细胞坏死不明显(坏死率<10%); 切缘未见癌; 3.(疤痕组织) 送检皮肤及皮下脂肪组织,真皮内纤维组织增生,符合瘢痕,未见癌; 4.(门静脉旁淋巴结) 淋巴结未见癌转移(0/3) EGFR(3+),HER2(0),KI |
| Clinical Treatment Records |
Model Data
Histopathological Images
Tumor growth curve
In vivo efficacy of SOCs
In vitro efficacy of SOCs
| 药物名称 | 靶点 | 药物说明 | 药效 | 细胞活率(%) |
|---|---|---|---|---|
| Lucatumumab | Mechanism of action: Trop-2-targeted ADC with a topoisomerase I inhibitor SN-38 payload Target: Trop-2 (trophoblast cell-surface antigen 2) | Indications: Triple-negative breast cancer, HR+/HER2− breast cancer, urothelial carcinoma Clinical application: Second-line and subsequent therapy, later-line therapy after platinum-based chemotherapy and immunotherapy | 17.07 | |
| SN38 | Mechanism of action: Topoisomerase I inhibitor (active metabolite of irinotecan) Target: Topoisomerase I | Indications: Colorectal cancer, small cell lung cancer, pancreatic cancer, etc. Clinical application: First-/second-line therapy (as a component of irinotecan) | 30.7027 | |
| DXD | Mechanism of action: Topoisomerase I inhibitor Target: Topoisomerase I | Indications: As a payload of ADC drugs (e.g., DS8201) Clinical application: Administered via ADC | 45.1891 | |
| DS8201 | Mechanism of action: HER2-targeted antibody-drug conjugate (ADC) containing a topoisomerase I inhibitor Target: HER2 receptor | Indications: HER2-positive breast cancer, gastric cancer, non-small cell lung cancer (HER2-mutated) Clinical application: Second-line and subsequent therapy (breast cancer), later-line therapy (other tumors) | 45.862 | |
| Trametinib | Mechanism of action: MEK1/2 inhibitor Target: MEK1/2 | Indications: BRAF V600-mutated melanoma, non-small cell lung cancer Clinical application: First-line combination with dabrafenib (melanoma) | 49.6177 | |
| Mitomycin C | Mechanism of action: Alkylating agent, induces DNA cross-linking Target: DNA | Indications: Gastric cancer, pancreatic cancer, bladder cancer (intravesical instillation), head and neck cancer Clinical application: Second-line and subsequent therapy | 57.9245 | |
| Oxaliplatin | Mechanism of action: Platinum compound, forms DNA adducts Target: DNA | Indications: Colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer Clinical application: First-line combination chemotherapy (e.g., FOLFOX) | 59.1221 | |
| 5-FU | Mechanism of action: Thymidylate synthase inhibitor, interferes with DNA synthesis Target: Thymidylate synthase (TS) | Indications: Colorectal cancer, gastric cancer, breast cancer, head and neck cancer, pancreatic cancer, etc. Clinical application: First-/second-line foundational drug for combination chemotherapy | 73.1878 | |
| Osimertinib | Mechanism of action: Third-generation EGFR-TKI, irreversible inhibitor Target: EGFR (including T790M mutation) | Indications: EGFR-mutated non-small cell lung cancer Clinical application: First-line therapy, second-line therapy for T790M-positive patients | 74.2445 | |
| Paclitaxel | Mechanism of action: Microtubule-stabilizing agent, antimitotic Target: Tubulin | Indications: Ovarian cancer, breast cancer, non-small cell lung cancer, pancreatic cancer, Kaposi's sarcoma Clinical application: First-/second-line therapy | 75.712 | |
| Docetaxel | Mechanism of action: Microtubule-stabilizing agent, antimitotic Target: Tubulin | Indications: Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer Clinical application: First-/second-line therapy | 79.256 | |
| Encorafenib | Mechanism of action: BRAF inhibitor Target: BRAF V600E/K | Indications: BRAF V600-mutated melanoma, colorectal cancer Clinical application: First-line combination with binimetinib (melanoma) | 80.0711 | |
| DM1 | Mechanism of action: Tubulin inhibitor, antimitotic Target: Tubulin | Indications: HER2-positive breast cancer (as a component of ADC drugs) Clinical application: Second-line and subsequent therapy (administered via ADC) | 82.1655 | |
| Cisplatin | Mechanism of action: Platinum compound, induces DNA cross-linking Target: DNA | Indications: Testicular cancer, ovarian cancer, bladder cancer, head and neck cancer, lung cancer, etc. Clinical application: Cornerstone drug of first-line chemotherapy | 82.5046 | |
| Vincristine | Mechanism of action: Vinca alkaloid, tubulin inhibitor Target: Tubulin | Indications: Lymphoma, leukemia, multiple myeloma, pediatric tumors Clinical application: First-line combination chemotherapy | 82.9262 | |
| Lapatinib | Mechanism of action: Dual HER2/EGFR tyrosine kinase inhibitor (TKI) Target: HER2, EGFR | Indications: HER2-positive breast cancer (combined with capecitabine) Clinical application: Second-line and subsequent therapy | 85.4335 | |
| Raltitrexed | Mechanism of action: Thymidylate synthase inhibitor Target: Thymidylate synthase (TS) | Indications: Colorectal cancer (patients intolerant to 5-FU) Clinical application: Second-line and subsequent therapy | 86.9926 | |
| Gemcitabine | Mechanism of action: Nucleoside analog, inhibits DNA synthesis Target: Ribonucleotide reductase, DNA polymerase | Indications: Pancreatic cancer, non-small cell lung cancer, breast cancer, bladder cancer, ovarian cancer Clinical application: First-line therapy (pancreatic cancer), first-/second-line therapy (other tumors) | 88.7893 | |
| Everolimus | Mechanism of action: mTOR inhibitor Target: mTOR | Indications: Renal cell carcinoma, neuroendocrine tumors, HR-positive breast cancer, SEGA Clinical application: Second-line and subsequent therapy | 90.1759 | |
| TAS-102 | Mechanism of action: Thymidine analog plus thymidine phosphorylase inhibitor Target: DNA synthesis + thymidine phosphorylase inhibition | Indications: Metastatic colorectal cancer, gastric cancer Clinical application: Third-line and subsequent therapy | 96.2861 |
药效图例:
绿色 = 低细胞活率,药效显著
红色 = 高细胞活率,耐药